13F Holdings
中文EN

NEPH NEPHROS INC

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1196298 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY20.4%
TTM net income YoY29.0%
TTM EPS YoY28.6%
Revenue 3-yr CAGR16.8%
Net income 3-yr CAGR—

Margins

Gross margin60.5%
Operating margin8.5%
Net margin8.9%
FCF margin—
EBITDA margin9.0%

Returns

ROE16.9%
ROA13.4%
ROIC (approx.)22.5%
Asset turnover1.51x

Leverage & solvency

Liabilities / assets18.0%
Debt / equity0.00x
Current ratio5.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.48x
Accruals ratio19.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY2022*2022-12-31FY20212021-12-31
Income statement
Revenue$18.79M$14.16M$14.24M$9.97M$10.22M
Cost of revenue$7.16M$5.44M$5.83M$5.24M$4.58M
Gross profit$11.62M$8.72M$8.40M$4.73M$5.63M
R&D expense$1.34M$906,000$873,000$1.25M$1.50M
SG&A expense$9.00M$7.68M$8.91M$7.59M$7.20M
Operating income$1.15M$6,000-$1.59M-$4.33M-$3.25M
Interest expense$1,000$1,000$2,000$20,000$41,000
Pretax income$1.21M$89,000-$1.57M——
Income tax$12,000$15,000$0$0$0
Net income$1.19M$74,000-$1.57M-$7.38M-$3.87M
EBITDA$1.29M$141,000-$1.38M-$4.12M-$3.06M
EPS (basic)0.110.01-0.15-0.73-0.41
EPS (diluted)0.110.01-0.15-0.73-0.41
Weighted avg. shares (diluted)10.97M10.60M10.39M10.30M10.02M
Balance sheet
Cash & equivalents$5.40M$3.76M$4.31M$3.63M$6.97M
Receivables$2.41M$1.78M$1.50M$1.29M$1.64M
Inventory$3.23M$2.62M$2.47M$3.15M$4.46M
Current assets$11.22M$8.30M$8.40M$8.26M$13.63M
PP&E, net$106,000$161,000$152,000$116,000$72,000
Goodwill$759,000$759,000$759,000$759,000$759,000
Intangibles$318,000$349,000$381,000$423,000$465,000
Total assets$13.64M$11.21M$11.86M$11.00M$17.65M
Current liabilities$2.77M$1.56M$2.11M$1.41M$2.39M
Long-term debt———$71,000$343,000
Total debt———$71,000$343,000
Total liabilities$3.44M$2.62M$3.50M$2.12M$2.90M
Shareholders' equity$10.20M$8.59M$8.36M$5.59M$11.70M
Net debt———-$3.56M-$6.63M
Shares outstanding10.64M10.54M10.54M10.30M10.26M
Cash flow statement
Operating cash flow$1.65M-$492,000$827,000-$3.23M-$1.42M
Capital expenditure—$55,000$75,000$137,000$36,000
Free cash flow—-$547,000$752,000-$3.37M-$1.45M
Investing cash flow$0-$50,000-$75,000-$137,000-$85,000
Financing cash flow-$5,000-$5,000-$79,000$34,000$237,000
Depreciation & amortization$140,000$135,000$214,000$218,000$192,000
Stock-based compensation$296,000$153,000$1.05M$982,000$1.26M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.